Updates are available Correction dated 2021-05-14
Click to view Correction: https://doi.org/10.1038/s41467-021-23559-1
Updates are available Correction dated 2024-02-05
Click to view Correction: https://doi.org/10.1038/s41467-024-45360-6
-
Authors
Axfors, Cathrine
Schmitt, Andreas M. https://orcid.org/0000-0002-9568-8164
Janiaud, Perrine
van’t Hooft, Janneke https://orcid.org/0000-0001-5303-1503
Abd-Elsalam, Sherief https://orcid.org/0000-0003-4366-2218
Abdo, Ehab F. https://orcid.org/0000-0002-9805-3850
Abella, Benjamin S. https://orcid.org/0000-0003-2521-0891
Akram, Javed
Amaravadi, Ravi K.
Angus, Derek C.
Arabi, Yaseen M.
Azhar, Shehnoor
Baden, Lindsey R.
Baker, Arthur W. https://orcid.org/0000-0002-0914-0291
Belkhir, Leila
Benfield, Thomas https://orcid.org/0000-0003-0698-9385
Berrevoets, Marvin A. H.
Chen, Cheng-Pin https://orcid.org/0000-0002-0629-9790
Chen, Tsung-Chia https://orcid.org/0000-0002-3461-5535
Cheng, Shu-Hsing https://orcid.org/0000-0002-6256-0527
Cheng, Chien-Yu
Chung, Wei-Sheng https://orcid.org/0000-0003-4240-5690
Cohen, Yehuda Z. https://orcid.org/0000-0001-6987-1478
Cowan, Lisa N.
Dalgard, Olav
de Almeida e Val, Fernando F.
de Lacerda, Marcus V. G. https://orcid.org/0000-0003-3374-9985
de Melo, Gisely C.
Derde, Lennie https://orcid.org/0000-0002-3577-5629
Dubee, Vincent https://orcid.org/0000-0002-9982-4741
Elfakir, Anissa
Gordon, Anthony C. https://orcid.org/0000-0002-0419-547X
Hernandez-Cardenas, Carmen M. https://orcid.org/0000-0002-0311-2978
Hills, Thomas https://orcid.org/0000-0003-0322-5822
Hoepelman, Andy I. M.
Huang, Yi-Wen
Igau, Bruno
Jin, Ronghua
Jurado-Camacho, Felipe
Khan, Khalid S.
Kremsner, Peter G.
Kreuels, Benno https://orcid.org/0000-0003-2315-8954
Kuo, Cheng-Yu
Le, Thuy https://orcid.org/0000-0002-3393-6580
Lin, Yi-Chun
Lin, Wu-Pu https://orcid.org/0000-0002-4206-7882
Lin, Tse-Hung
Lyngbakken, Magnus Nakrem https://orcid.org/0000-0002-5994-9304
McArthur, Colin
McVerry, Bryan J. https://orcid.org/0000-0002-1175-4874
Meza-Meneses, Patricia https://orcid.org/0000-0002-3931-3114
Monteiro, Wuelton M.
Morpeth, Susan C.
Mourad, Ahmad https://orcid.org/0000-0002-3149-597X
Mulligan, Mark J.
Murthy, Srinivas
Naggie, Susanna
Narayanasamy, Shanti https://orcid.org/0000-0002-6667-2868
Nichol, Alistair
Novack, Lewis A.
O’Brien, Sean M.
Okeke, Nwora Lance
Perez, Léna
Perez-Padilla, Rogelio
Perrin, Laurent https://orcid.org/0000-0002-1916-6639
Remigio-Luna, Arantxa
Rivera-Martinez, Norma E. https://orcid.org/0000-0002-6716-1234
Rockhold, Frank W. https://orcid.org/0000-0003-3732-4765
Rodriguez-Llamazares, Sebastian https://orcid.org/0000-0002-7864-8953
Rolfe, Robert
Rosa, Rossana
Røsjø, Helge
Sampaio, Vanderson S. https://orcid.org/0000-0001-7307-8851
Seto, Todd B.
Shahzad, Muhammad
Soliman, Shaimaa
Stout, Jason E. https://orcid.org/0000-0002-6698-8176
Thirion-Romero, Ireri
Troxel, Andrea B.
Tseng, Ting-Yu
Turner, Nicholas A. https://orcid.org/0000-0003-0650-4894
Ulrich, Robert J. https://orcid.org/0000-0002-3217-5062
Walsh, Stephen R. https://orcid.org/0000-0002-0817-9370
Webb, Steve A.
Weehuizen, Jesper M.
Velinova, Maria
Wong, Hon-Lai
Wrenn, Rebekah
Zampieri, Fernando G. https://orcid.org/0000-0001-9315-6386
Zhong, Wu https://orcid.org/0000-0002-0536-620X
Moher, David https://orcid.org/0000-0003-2434-4206
Goodman, Steven N.
Ioannidis, John P. A. https://orcid.org/0000-0003-3118-6859
Hemkens, Lars G. https://orcid.org/0000-0002-3444-1432
-
Funding
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Laura and John Arnold Foundation
Uppsala Universitet
Svenska Läkaresällskapet
Sweden-America Foundation
- License Information
-
More Information
Article History
Received: 2 October 2020
Accepted: 15 March 2021
First Online: 15 April 2021
Change Date: 5 February 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-024-45360-6
Change Date: 14 May 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-021-23559-1
Competing interests
: B.S.A. and R.K.A. are the primary investigators of the Prevention and Treatment of COVID19 with Hydroxychloroquine (PATCH) trial, funded by a philanthropic gift. R.K.A reports being founder with equity of Pinpoint Therapeutics and Immunacell, and personal fees from Sprint Biosciences and Deciphera, outside the submitted work. D.C.A. reports personal fees from Ferring Pharmaceuticals, Inc., Bristol-Myers Squibb, and Bayer AG, other from Alung Technologies, Inc., outside the submitted work; in addition, D.C.A. has pending patents for Selepressin—compounds, compositions, and methods for treating sepsis to Ferring, B.V., and Proteomic biomarkers of sepsis in elderly patients pending to University of Pittsburgh. Y.M.A. reports that he is the principal investigator on a clinical trial of lopinavir–ritonavir and interferon for Middle East respiratory syndrome (MERS) and that he was a nonpaid consultant on therapeutics for MERS-coronavirus (CoV) for Gilead Sciences and SAB Biotherapeutics. He is a coinvestigator on the Randomized, Embedded, Multi-factorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP), a board member of the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC), and the Lead-Co Chair of the Think20 (T20) Taskforce for COVID-19. Brigham and Women’s Hospital, PRA Health Science, and Cliniques universitaires Saint-Luc received funds from Sanofi. T.B. reports grants from Pfizer, Novo Nordisk Foundation, Simonsen Foundation, Lundbeck Foundation, and Kai Hansen Foundation; grants and personal fees from GSK, Pfizer, Boehringer Ingelheim, and Gilead; and personal fees from MSD, all outside the submitted work. Y.Z.C., L.N.C., B.I., and L.P. are employees of Sanofi. The COV-HCQ and COMIHY trials were supported by the German Federal Ministry of Education and Research (EudraCT number 2020-001224-33) and the German Federal Ministry of Health (EudraCT number 2020-001512-26). L.D. reports grants from EU FP7-HEALTH-2013-INNOVATION-1, grant number 602525, grants from H2020 RECOVER, grant agreement no. 101003589, during the conduct of the study; and is a member of the COVID-19 guideline committee SCCM/ESICM/SSC, member of the ESICM COVID-19 taskforce, and chair of the Dutch intensivists (NVIC) taskforce infectious threats. V.D. reports nonfinancial support from MSD France and from Sanofi Aventis France, outside the submitted work. A.E. is an employee of Ividata Life Sciences and works as an external contractor for Sanofi. A.C.G. received grant funding from an NIHR Research Professorship (RP-2015-06-18), support from the NIHR Imperial Biomedical Research Centre, and consulting fees paid to his institution from GlaxoSmithKline and Bristol-Myers Squibb. T.H. reports grants from the Health Research Council of New Zealand, during the conduct of the study. A.I.M.H. reports grants from ZonMw, Netherlands organisation for Health Research and Development, during the conduct of the study. HYDRA trial was an investigator-initiated study supported by Sanofi, CONACYT (National Council of Science and Technology of Mexico) and by the participating centers. Thuy Le reports grants from Gilead Sciences, outside the submitted work. B.J.M. reports grants from NIH/NHLBI, and from Bayer Pharmaceuticals, Inc., outside the submitted work. S.M. receives funding as the Innovative Medicines Canada Chair in Pandemic Preparedness. C.M. reports grants from the Health Research Council of New Zealand. M.J.M. reports having received the HCQ drug from the New York State government, during the conduct of the study; grants from Lilly, Pfizer, Sanofi, and personal fees from Meissa, outside the submitted work; in addition, M.J.M. has a patent anti-Zika monoclonal ab/ Emory Univ pending. A.N. is supported by a Health Research Board of Ireland Clinical Trial Network Award (HRB-CTH-2014-012). L.P. is an employee of Excelya and works as an external contractor for Sanofi. F.W.R. reports personal fees from Merck Research Labs, Novartis, Lilly, Sanofi, NovoNordisk, KLSMC, Tolerion, Rhythm, UCB, AstraZeneca, Janssen, Merck KGaA, Sarepta, Eidos, Amgen, Phathom, outside the submitted work; and having equity interest in GlaxoSmithkline, Athira Pharma, DataVant, Spencer Healthcare. S.R.W. reports receiving a grant from Sanofi during the conduct of the study and grants from NIH-NIAID outside the submitted work, and having conducted vaccine (HIV, Zika) clinical trials funded by Janssen. S.A.W. reports grants from National Health and Medical Research Council (Australia), grants from Minderoo Foundation, from Health Research Council (New Zealand), and from Medical Research Future Fund (Australia), during the conduct of the study. J.M.W. reports grants from ZonMw, Netherlands organisation for Health Research and Development, during the conduct of the study. F.G.Z. was part of the Coalition 1 trial partially supported by EMS Pharmaceuticals, has received previous grants from Bactiguard, Sweden, outside the submitted work, and support from Baxter LA for another clinical trial in critically ill patients. None of the other authors have any competing interests to declare.
